Agenda
IACRLRD Symposium XXIV: Molecular Approaches to Leukemia in the 21st Century:
Biology, Outcome Prediction and Personalized Therapy
The Ohio State University Comprehensive Cancer Center –
Arthur G. James Cancer Hospital and Richard J. Solove Research Institute
Mershon Auditorium
Columbus, Ohio
October 15-16, 2009
OCTOBER 15
7:45 - 8 a.m.
Welcome and Opening Remarks
Clara D. Bloomfield, MD, IACRLRD President
The Ohio State University Comprehensive Cancer Center – James Cancer Hospital
and Solove Research Institute, Columbus, Ohio
Steven G. Gabbe, MD
Senior Vice President for Health Sciences
CEO, The Ohio State University Medical Center
Columbus, Ohio
CEO, The Ohio State University Medical Center
Columbus, Ohio
Michael A. Caligiuri, MD*
Director, The Ohio State University Comprehensive Cancer Center
CEO, James Cancer Hospital and Solove Research Institute, Columbus, Ohio
CEO, James Cancer Hospital and Solove Research Institute, Columbus, Ohio
8 - 8:40 a.m.
Yohei Ito Memorial Lecture
Introduction by ToshikiWatanabe, MD, PhD, IACRLRD Senior Vice President, Japan
Stem Cells, Pluripotency and Nuclear Reprogramming
Rudolf Jaenisch, MD
Massachusetts Institute of Technology
Whitehead Institute, Cambridge, Massachusetts
Whitehead Institute, Cambridge, Massachusetts
Lymphoid Leukemias: Emerging Concepts for Innovative Therapies
Session Chairs: Jacques Ghysdael, MD, PhD*, France and Dieter Hoelzer, MD, PhD, Germany
8:45 - 9:05 a.m.
Hairy Cell Leukemia: A Successful Model for Experimental Therapeutics in Orphan Diseases
Michael R. Grever, MD
The Ohio State University Comprehensive Cancer Center – James Cancer Hospital
and Solove Research Institute, Columbus, Ohio
9:10 - 9:30 a.m.
B Cell Receptor Signaling in Lymphoid Malignancies
Louis M. Staudt, MD, PhD
National Cancer Institute, Bethesda, Maryland
9:35 - 9:55 a.m.
Novel Targeted Therapies in Chronic Lymphocytic Leukemia
John C. Byrd, MD
The Ohio State University Comprehensive Cancer Center – James Cancer Hospital
and Solove Research Institute, Columbus, Ohio
10 - 10:20 a.m.
Break
10:20 - 10:50 a.m.
Keynote Address
Novel Therapeutic Approaches in Acute Lymphoblastic Leukemia
Novel Therapeutic Approaches in Acute Lymphoblastic Leukemia
Richard A. Larson, MD
University of Chicago Medical Center, Chicago, Illinois
10:55 - 11:15 a.m.
Prognostic Molecular Markers in Acute Lymphoblastic Leukemia
Claudia D. Baldus, MD
Charité, University Hospital Berlin, Berlin, Germany
11:20 - 11:40 a.m.
Biologic Insights, Novel Therapies and Social Considerations for Adolescent Acute Lymphoblastic Leukemia
Wendy Stock, MD
University of Chicago Medical Center, Chicago, Illinois
11:45 a.m. - 12:05 p.m.
Risk-Adapted Approaches to Cure Childhood Acute Lymphoblastic Leukemia: A Lesson from the Pediatricians
Andrea Biondi, MD*
University of Milano-Bicocca, Monza, Italy
12:10 - 1:20 p.m.
Lunch break
Genetics and Epigenetics of Acute Leukemia
Session Chairs: Jonathan D. Licht, MD, USA, and Cheryl L.Willman, MD, USA
1:20 - 1:50 p.m.
Keynote Address
Genome-Wide Approaches to Discovery and Therapeutic Targeting of Novel Leukemogenic Mechanisms
Genome-Wide Approaches to Discovery and Therapeutic Targeting of Novel Leukemogenic Mechanisms
James R. Downing, MD
t. Jude Children’s Research Hospital, Memphis, Tennessee
1:55 - 2:15 p.m.
The Biology and Therapeutic Targeting of Leukemia Stem Cells
Craig T. Jordan, PhD
James P.Wilmot Cancer Center, University of Rochester School of Medicine,
Rochester, New York
2:20 - 2:40 p.m.
Epigenetics in Leukemia Stem Cells
Jean-Pierre Issa, MD
The University of Texas M.D. Anderson Cancer Center, Houston, Texas
2:45 - 3:05 p.m.
Role of Leukemogenic Fusion Proteins in Acute Leukemia
Stefan K. Bohlander, MD, PhD
University of Munich Hospital Grosshadern, Munich, Germany
3:10 - 3:40 p.m.
Keynote Address
Biologic and Clinical Significance of Monosomal Karyotypes in Acute Myeloid Leukemia
Bob Löwenberg, MD, PhD
Erasmus University Medical Center, Rotterdam, The Netherlands
3:45 – 4:05 p.m.
Break
4:05 - 4:25 p.m.
Novel Therapeutic Approaches to Acute Promyelocytic Leukemia
Martin S. Tallman, MD
Northwestern University Feinberg School of Medicine, Chicago, Illinois
New Paradigms in Myelodysplastic Syndromes
Session Chairs: Steve D. Gore, MD, USA and Charles A. Schiffer, MD, USA
4:30 - 4:50 p.m.
Biologic Response Signatures in Myelodysplastic Syndromes
Alan F. List, MD
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida
4:55 - 5:15 p.m.
Azanucleosides: Cytotoxic vs Epigenetic Treatment for Myelodysplastic Syndromes
Michael Lübbert, MD
University of Freiburg Medical Center, Freiburg, Germany
5:20 - 6 p.m.
Kenneth McCredie Memorial Lecture
Introduction by Varsha Gandhi, PhD, USA
Prognostic vs. Predictive Markers in Acute Myeloid Leukemia: Molecular Guidance to Treatment
Hartmut Döhner, MD
University Hospital of Ulm, Ulm, Germany
OCTOBER 16
Risk-Adapted Stratification and Treatments in Acute Myeloid Leukemia
Session Chairs: Gail J. Roboz, MD, USA and Maria R. Baer, MD, USA
8:30 - 8:50 a.m.
Cytogenetic-Risk Assessment: A Decade Later
David Grimwade, PhD*
King’s College London School of Medicine, Guy’s Hospital, London, United Kingdom
8:55 - 9:15 a.m.
Integration of MicroRNA and Gene Expression Profiles Uncover Novel Molecular Subsets of Acute Myeloid Leukemia
Guido Marcucci, MD
The Ohio State University Comprehensive Cancer Center – James Cancer Hospital
and Solove Research Institute, Columbus, Ohio
9:20 - 9:40 a.m.
Loss of wt-FLT3 as Disease Modifier in Acute Myeloid Leukemia – Insights on the Biology and the Impact on Prognosis
Christian Thiede, MD, PhD
University Clinic Carl Gustav Carus at the Technical University of Dresden,
Dresden, Germany
9:45 - 10:05 a.m.
Applying Pharmacogenomics to Leukemia Treatment: AreWe There Yet?
Mary V. Relling, PharmD
St. Jude Children’s Research Hospital, Memphis, Tennessee
10:10 - 10:30 a.m.
Break
10:30 - 10:50 a.m.
Gene Mutations in Acute Myeloid Leukemia: Predisposing Factors, Predictive Markers and Prognosticators
Konstanze Döhner, MD
University Hospital of Ulm, Ulm, Germany
10:55 - 11:15 a.m.
Targeting Aberrantly Activated Pathways in Myeloid Malignancies: The Role of Ras and Rho Small GTPases
Tomoki Naoe, MD, PhD
Nagoya University Graduate School of Medicine, Nagoya, Japan
11:20 - 11:50 a.m.
Keynote Address
Have Molecular Targeted Agents Maintained Their Therapeutic Promise in Acute Myeloid Leukemia?
Alan K. Burnett, MD
School of Medicine, Cardiff University, Cardiff, United Kingdom
11:55 a.m. - 12:15 p.m.
Older Acute Myeloid Leukemia Patients:Who to Treat,When to Treat, How to
Treat. The Role of a Prognostic Score in Treatment Decision Making
Hervé Dombret, MD, PhD
Saint-Louis Hospital, Paris, France
12:20 - 12:40 p.m.
Hematopoietic Stem Cell Transplants in Elderly Acute Myeloid Leukemia
Dietger Niederwieser, MD
University of Leipzig, Leipzig, Germany
12:45 - 1:25 p.m.
Charlotte Friend Memorial Lecture
Introduction by Roland Mertelsmann, MD, PhD* Germany
When Biology Guides Treatment: Chronic Myelogenous Leukemia, a Paradigm for
Rational Therapies in Leukemia
Brian J. Druker, MD
Oregon Health and Science University Knight Cancer Institute, Portland, Oregon
1:30 - 2:55 p.m.
Lunch break
2:55 - 3:15 p.m.
Modern Designs of Clinical Trials Targeting Distinct Molecular Subsets of Acute
Myeloid Leukemia
Elihu H. Estey, MD
University ofWashington School of Medicine
Fred Hutchinson Cancer Research Center, Seattle,Washington
Diagnosis, Prognostication and Treatment of ChronicMyelogenous Leukemia in the Era of Tyrosine Kinase Inhibitors
Session Chairs: Andreas Hochhaus, MD*, Germany, and Steven M. Devine, MD, USA
3:20 - 3:40 p.m.
Gene Expression Profiling in ChronicMyelogenous Leukemia
Jerald P. Radich, MD
University ofWashington School of Medicine
Fred Hutchinson Cancer Research Center, Seattle, Washington
3:45 - 4:05 p.m.
Clinical Options for Resistant, Relapsed, or Transformed ChronicMyelogenous
Leukemia
Hagop M. Kantarjian, MD
University of Texas M.D. Anderson Cancer Center, Houston, Texas
4:10 - 4:30 p.m.
Uncovering the Mechanisms of Blast Transformation in ChronicMyelogenous
Leukemia
Danilo Perrotti, MD, PhD
The Ohio State University Comprehensive Cancer Center – James Cancer Hospital
and Solove Research Institute, Columbus, Ohio
4:35 - 4:55 p.m.
Monitoring Minimal Residual Disease in ChronicMyelogenous Leukemia in the
Gleevec Era:When to Observe,When to Intervene?
Giuseppe Saglio, MD, IACRLRD Vice President
University of Turin, Turin, Italy
5 - 5:20 p.m.
Beyond Life-Long Administration of Tyrosine Kinase Inhibitors:What is Next for
ChronicMyelogenous Leukemia Patients?
Rüdiger Hehlmann, MD, IACRLRD Secretary General
University of Heidelberg, Mannheim, Germany
5:25 - 6:15 p.m.
IACRLRD Assembly, Concluding Remarks and Closing Ceremony
Clara D. Bloomfield, MD, IACRLRD President
*An IACRLRD World Committee Member
